Therefore, we believe that sorafenib has two effects on FAK: on the one hand, FAK phosphorylation was inhibited by sorafenib, reducing tumourigenicity30,31; the other hand, this study found that FAK entered the nuclear under sorafenib treatment, and led to the degradation of p53, promoting tumour survival. Here, PTK2 is linked to neoplasm.